Medtech startup Osteopore leads the way for regenerative solutions

Listed on the Australian Securities Exchange, Osteopore is a medtech startup made possible through research conducted by the National University of Singapore, National University Hospital and Temasek Polytechnic. To date, the company is the global leader in regenerative solutions and its technology boasts 50,000 successful treatments using patients’ cells and growth factors.

In collaboration with clinicians and researchers, Osteopore produces medical implants to meet the needs of both tissue and bone reconstruction as well as restoration. Its bioresorbable implant is the first of its kind to be successfully developed and commercialised for surgical use and is presently used by surgeons across Asia, Europe, Australia and the Americas.

In an insightful conversation with Mark Leong, Chairman of Osteopore & Dr Lim Jing, COO & CTO of Osteopore, we discover that the future of healthcare in rebuilding human tissues is already here. Both gentlemen speak about how the company’s regenerative medicine and tissue engineering technology has benefited patients across the globe, including its plans to further leverage technology to improve patient outcomes and enhance more lives.

Additionally, the duo touch on:

Different examples of tissue regeneration and the circumstances in which this technology can be utilised.
Success stories from patients who have been treated with Osteopore’s innovative regenerative implants.
The evolution of tissue regeneration technology and what we can expect in the near future.
The firm’s development of bioprinting technology and how this has impacted patients’ lives in positive ways.
What’s next in the pipeline for Osteopore and future opportunities that can change the face of healthcare.